AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is currently conducting a Phase I/IIa study titled A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors. The study aims to evaluate the safety, tolerability, and preliminary efficacy of AZD5335, an antibody-drug conjugate, both as a standalone treatment and in combination with other anti-cancer agents in patients with advanced solid tumors.
The study is testing AZD5335, an intravenous antibody-drug conjugate, either alone or in combination with other drugs such as Saruparib, Bevacizumab, Carboplatin, and AZD9574. These combinations are designed to enhance anti-cancer activity in patients with solid tumors.
This interventional study is randomized and follows a sequential intervention model, with no masking involved. Its primary purpose is treatment, focusing on evaluating the safety and efficacy of AZD5335 across different modules.
The study began on June 5, 2023, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 23, 2025, indicating ongoing progress in the study.
The outcome of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, as successful results may enhance the company’s oncology portfolio. This development is crucial in the competitive landscape of cancer treatment, where innovation is key to maintaining market leadership.
The study is currently recruiting, with further details available on the ClinicalTrials portal.